Historical Valuation
Kalvista Pharmaceuticals Inc (KALV) is now in the Fair zone, suggesting that its current forward PS ratio of 11.93 is considered Fairly compared with the five-year average of -4.01. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 11.66 to 40.29 according to relative valuation methord.
Relative Value
Fair Zone
11.66-40.29
Current Price：15.82
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kalvista Pharmaceuticals Inc (KALV) has a current Price-to-Book (P/B) ratio of 19.08. Compared to its 3-year average P/B ratio of 5.00 , the current P/B ratio is approximately 281.81% higher. Relative to its 5-year average P/B ratio of 4.05, the current P/B ratio is about 370.91% higher. Kalvista Pharmaceuticals Inc (KALV) has a Forward Free Cash Flow (FCF) yield of approximately -21.48%. Compared to its 3-year average FCF yield of -23.17%, the current FCF yield is approximately -7.28% lower. Relative to its 5-year average FCF yield of -22.55% , the current FCF yield is about -4.73% lower.
P/B
Median3y
5.00
Median5y
4.05
FCF Yield
Median3y
-23.17
Median5y
-22.55
Competitors Valuation Multiple
AI Analysis for KALV
The average P/S ratio for KALV competitors is 4.78, providing a benchmark for relative valuation. Kalvista Pharmaceuticals Inc Corp (KALV.O) exhibits a P/S ratio of 11.93, which is 149.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KALV
1Y
3Y
5Y
Market capitalization of KALV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KALV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KALV currently overvalued or undervalued?
Kalvista Pharmaceuticals Inc (KALV) is now in the Fair zone, suggesting that its current forward PS ratio of 11.93 is considered Fairly compared with the five-year average of -4.01. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 11.66 to 40.29 according to relative valuation methord.
What is Kalvista Pharmaceuticals Inc (KALV) fair value?
KALV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 11.66 to 40.29 according to relative valuation methord.
How does KALV's valuation metrics compare to the industry average?
The average P/S ratio for KALV's competitors is 4.78, providing a benchmark for relative valuation. Kalvista Pharmaceuticals Inc Corp (KALV) exhibits a P/S ratio of 11.93, which is 149.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Kalvista Pharmaceuticals Inc (KALV) as of Jan 10 2026?
As of Jan 10 2026, Kalvista Pharmaceuticals Inc (KALV) has a P/B ratio of 19.08. This indicates that the market values KALV at 19.08 times its book value.
What is the current FCF Yield for Kalvista Pharmaceuticals Inc (KALV) as of Jan 10 2026?
As of Jan 10 2026, Kalvista Pharmaceuticals Inc (KALV) has a FCF Yield of -21.48%. This means that for every dollar of Kalvista Pharmaceuticals Inc’s market capitalization, the company generates -21.48 cents in free cash flow.
What is the current Forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV) as of Jan 10 2026?
As of Jan 10 2026, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/E ratio of -4.13. This means the market is willing to pay $-4.13 for every dollar of Kalvista Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kalvista Pharmaceuticals Inc (KALV) as of Jan 10 2026?
As of Jan 10 2026, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/S ratio of 11.93. This means the market is valuing KALV at $11.93 for every dollar of expected revenue over the next 12 months.